^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)

    i
    Other names: LRIG1, Leucine Rich Repeats And Immunoglobulin Like Domains 1, LIG-1, LIG1, Leucine-Rich Repeats And Immunoglobulin-Like Domains Protein 1, Ortholog Of Mouse Integral Membrane Glycoprotein LIG-1, Leucine-Rich Repeat Protein, LRIG1, DKFZP586O1624
    2d
    α-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer. (PubMed, Cell Death Dis)
    This predisposes to genomic instability and pancreatic preneoplastic lesion development. These findings uncover a metabolic-epigenetic axis in dysmetabolic PDAC, highlighting how metabolite-driven epigenetic changes compromise DNA repair and drive tumorigenesis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • PDX1 (Pancreatic And Duodenal Homeobox 1) • LIG3 (DNA Ligase 3)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    12d
    TMEM106C, BSG, COPE, CDCA8, KPNA2, LIG1, UQCRH, and CCT5: Predictive of Survival and Immunotherapy Resistance in Hepatocellular Carcinoma. (PubMed, Hum Mutat)
    Furthermore, the identified biomarker CDCA8 represents a promising therapeutic target warranting further investigation. These discoveries provide novel evidence on senescence in HCC, which may tailor the pharmacological interventions to improve the clinical management.
    Journal • IO biomarker
    |
    LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • CDCA8 (Cell Division Cycle Associated 8) • KPNA2 (Karyopherin Subunit Alpha 2)
    16d
    Ataxia-telangiectasia mutated kinase inhibition overcomes gemcitabine resistance in intrahepatic cholangiocarcinoma via DNA ligase I-dependent repair vulnerability. (PubMed, Cancer Gene Ther)
    In xenograft models, AZD0156 combined with cisplatin substantially suppressed tumor growth compared to monotherapy, with acceptable tolerability profiles. These findings identify ATM inhibition as a promising strategy to overcome gemcitabine resistance in CCA, particularly in tumors with compromised alt-NHEJ repair capacity, providing a mechanistic rationale for clinical development of this combination therapy.
    Journal
    |
    LIG1 (DNA Ligase 1) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
    |
    cisplatin • gemcitabine • AZD0156
    22d
    A novel tumor-progressing fibroblast signature derived from single-cell RNA sequencing enables prognostic stratification and reveals RNF11 as a functional regulator in bladder cancer. (PubMed, Front Mol Biosci)
    Functional characterization showed that RNF11 regulates proliferation and migration of bladder cancer. These findings highlight the prognostic value of CAF signatures and provide a framework for precision medicine approaches in bladder cancer management.
    Journal
    |
    FOXA1 (Forkhead Box A1) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
    2ms
    Functional Impact of Glycosylation of LRIG1 on EGFR Proteostasis in Cancer. (PubMed, J Biochem)
    Our findings suggest that the absence of glycosylation at N74 site enhances LRIG1-EGFR binding, providing an example of glycosylation negatively regulating protein-protein interaction. This mechanism provides insights into the importance of glycosylation deficiency in cancer biology.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
    2ms
    Homologous Recombination Is Associated with Enhanced Anti-Tumor Innate Immunity and Favorable Prognosis in Head and Neck Cancer. (PubMed, Cancers (Basel))
    Together, our findings provide a comprehensive overview of the HR pathway in HNSCC, highlighting the dual role of HR proteins in both genomic maintenance and immune regulation. The consistent upregulation of HR proteins, their association with disease progression, and potential immunogenic effects underscore their promise as diagnostic/prognostic biomarkers and therapeutic targets in HNSCC.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • RAD51 (RAD51 Homolog A) • STING (stimulator of interferon response cGAMP interactor 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • STAT1 (Signal Transducer And Activator Of Transcription 1) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • RPA1 (Replication Protein A1) • RPA2 (Replication Protein A2)
    2ms
    LIG1 overexpression enhances DNA repair and immune escape leading to poor prognosis in osteosarcoma. (PubMed, Eur J Med Res)
    LIG1 drives OS progression and immune evasion by remodeling the tumor microenvironment. It serves as an independent prognostic biomarker and a potential therapeutic target, particularly in combination with immune checkpoint blockade.
    Journal
    |
    LIG1 (DNA Ligase 1) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1)
    3ms
    Molecular Resonance Quantification and Label-Free Interactome Characterization of Total Proteome of Tumor Specimens Decipher Responder and Success Predictors in Colorectal Cancer Patients Treated With Panitumumab. (PubMed, Cancer Med)
    Combination of PIMS and NPOT coupled to label-free quantitative proteomics point towards the distinct panitumumab mode of action in CRC patients and highlights specific proteins as prognostic biomarkers which need further validation in a bigger cohort and multicentric investigation, ideally involving patient registry follow up data.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • POLD1 (DNA Polymerase Delta 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1) • ENO1 (Enolase 1) • YBX1 (Y-Box Binding Protein 1) • CTNND1 (Catenin Delta 1) • ITGB2 (Integrin Subunit Beta 2) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • NT5C (5', 3'-Nucleotidase, Cytosolic) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1) • HSPA4 (Heat Shock Protein Family A (Hsp70) Member 4) • ITGB1 (Integrin Subunit Beta 1) • PPM1G (Protein Phosphatase, Mg2+/Mn2+ Dependent 1G) • YWHAZ (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Zeta) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8) • NCAPD2 (Non-SMC Condensin I Complex Subunit D2)
    |
    Vectibix (panitumumab)
    3ms
    XPF mediates 3' flap processing for FEN1-independent Okazaki fragment maturation. (PubMed, bioRxiv)
    Targeting this compensatory mechanism could provide new therapeutic strategies to selectively impair cancer cell survival under pre-existed replication stress. XPF is recruited to DNA replication forks in mouse or human cells of functional deficiency of FEN1 due to genetic mutations or chemical inhibition.XPF gene deficiency or chemical inhibition results in accumulation of 3' flaps and replicative DNA single-stranded breaks.Functional deficiency of XPF and FEN1 displays a synergy in inducing genome instability and cell death in human cancer cells.
    Journal
    |
    LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • FEN1 (Flap Structure-Specific Endonuclease 1)
    4ms
    LRIG1-3 in gliomas: LRIG1 protein expression decreased in higher grade gliomas. (PubMed, Oncotarget)
    LRIG3 mRNA expression, in contrast, was significantly higher in grade II gliomas compared to surrounding control tissue, whereas chemotherapy did not significantly affect expression levels in glioblastoma. Our results reinforce suggestions that LRIG1-3 could function as diagnostic markers and therapeutic targets in the treatment of gliomas.
    Journal
    |
    LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • LRIG2 (Leucine Rich Repeats And Immunoglobulin Like Domains 2) • LRIG3 (Leucine-rich repeats and immunoglobulin-like domains protein 3)
    4ms
    Targeting MERTK tyrosine kinase: Virtual screening and molecular dynamics insights for anti-cancer drug development. (PubMed, PLoS One)
    We used known compound UNC2025 as positive control and one million compounds was retrieved from different databases (OTAVA, ZINC, ChEMBL) and docked with MERTK protein...The study finds critical residues which serve a vital part in binding with the inhibitor and the active site of the MERTK protein, i.e., Phe598, Gly599, Lys619, Arg629, Glu633, Glu637, Arg722, Asp723, Arg727, Asp741, Gly743, Leu744, Lys746, Arg758, Ala760, and Lys761 through decomposed binding free energy analysis. This study focuses on the pursuit of several MERTK protein targets, which could have consequences for the development of novel therapeutics for various cancers.
    Journal
    |
    MERTK (MER Proto-Oncogene, Tyrosine Kinase) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • LIG3 (DNA Ligase 3)
    |
    UNC2025
    5ms
    Exploring the effect of capsaicin on gene expression and chemotherapy sensitization in gastric cancer cells. (PubMed, Eur J Med Res)
    Capsaicin could inhibit DNA repair, thereby inhibited cell viability and improved the sensitivity of chemotherapy in gastric cancer cells.
    Journal • PARP Biomarker
    |
    LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • FEN1 (Flap Structure-Specific Endonuclease 1)
    |
    5-fluorouracil • oxaliplatin